Evaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral Anticoagulation

Kristiansen, Charlotte; Lassen, Jens Flensted; Dahler-Eriksen, Bjarne Steen; Dahler-Eriksen, Kathrine; Larsen, Torben Bjerregaard; Brandslund, Ivan

doi:10.1016/s0049-3848(99)00222-4

Cited by 12 publications

(12 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Warfarin and acenocoumarol are structurally related, and have a mechanism of action similar to that of vitamin K antagonists; however, they exhibit a marked difference in dosage requirements and variability in anticoagulation response. Hence, the large difference in their elimination rates may lead to serious overdosage upon transition from one drug to the other 12 . No complications were reported during the transition period and short term follow‐up in the presented patient by using suggested scheme.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Transition from Acenocoumarol to Warfarin in a 12-year-old Child

Hakacova¹,

Björkhem²,

Hanséus³

2011

Congenital Heart Disease

View full text Add to dashboard Cite

The types of coumadin anticoagulants registered and available for use differ between countries. Most frequently used coumadin anticoagulants are warfarin and acenocoumarol. Under several specific conditions, transition from one coumarin to another is required. Because of different pharmacokinetic and pharmacodynamic characteristics, the transition from one type of coumarol to another type can be challenging. There are no studies that address this issue in children. We present the case report of transition treatment between acenocoumarol and warfarin in a 12-year-old child with prosthetic mitral valve.

show abstract

Section: Discussionmentioning

confidence: 84%

“…Previously, Kristiansen et al. calculated transition factors in transition from acenocoumarol to phenoprocoumon in adults 12 . According to average equipotent doses, a stepwise increase in warfarin dose was calculated based on the elimination halftimes of the two drugs.…”

Section: Discussionmentioning

confidence: 99%

Transition from Acenocoumarol to Warfarin in a 12-year-old Child

Hakacova¹,

Björkhem²,

Hanséus³

2011

Congenital Heart Disease

View full text Add to dashboard Cite

show abstract

“…In Schwebe et al wurden die stationären Kosten von gastrointestinalen Blutungen ermittelt, die als unerwünschte Arzneimittelwirkung der Phenprocoumon Therapie auftraten [15]. Kristiansen et al haben die Austauschbarkeit von Phenprocoumon und Warfarin hinsichtlich Nebenwirkungen und Wirksamkeit gezeigt [16]. Die Kosten für durch Phenprocoumon verursachte gastrointestinale Blutungen werden daher als vergleichbar mit den von Warfarin verursachten Kosten extrakranialer schwerer Blutungen angesehen.…”

Section: Modell Inputsunclassified

“…Bei [19]. In der Base Case Analyse ergaben sich für einen 65-jährigen Patienten (CHADS 2 Score von 2,1) unter Therapie mit Apixaban 11,16 QALYs und mit Warfarin 10,69 QALYs [19]. Die zugehörigen Kosten beliefen sich für Apixaban auf $ 86.007 und $ 94.941 für Warfarin [19].…”

Section: Modell Inputsunclassified

See 1 more Smart Citation

Kosteneffektivität von Apixaban zur Verhinderung von Schlaganfällen bei Vorhofflimmern in Deutschland

Reimer

Schöffski

2013

PharmacoEcon. Ger. Res. Artic.

View full text Add to dashboard Cite

Background and Objective: Apixaban was shown to be superior to warfarin and acetylsalicylic acid in preventing stroke in patients with atrial fibrillation and at least one additional risk factor. This study compared the cost effectiveness of apixaban versus warfarin and acetylsalicylic acid in this patient population in Germany. Methods: We constructed a lifetime Markov model with 12 health states, based on the results of the Aristotle and Averroes trial, to evaluate the cost effectiveness of apixaban from the social healthcare perspective. Our base-case assumed a cohort of 65-year old patients with a CHADS 2 Score of 2.1. We used a 1-month cycle-length. The outcome was measured in quality-adjusted life-years (QALYs), costs and incremental-cost-effectiveness ratios (ICER). The robustness of the model was tested with one and two way sensitivity analyses. A probabilistic sensitivity analysis was also performed. Results: Under base case conditions, total costs per patient were € 33,427 and € 33,118 for apixaban and warfarin. Corresponding QALYs were 10.79 and 10.06 in the lifetime Markov model. The ICER was € 423 per QALY. Monte Carlo simulation demonstrated apixaban was cost-effective in 86 % and

show abstract

Pharmacology of Vitamin K Antagonists

Shin

Kayser

2011

Inpatient Anticoagulation

View full text Add to dashboard Cite

Evaluation of a Simple Dosage Scheme for Transition from Phenprocoumon to Warfarin in Oral Anticoagulation

Cited by 12 publications

References 11 publications

Transition from Acenocoumarol to Warfarin in a 12-year-old Child

Transition from Acenocoumarol to Warfarin in a 12-year-old Child

Kosteneffektivität von Apixaban zur Verhinderung von Schlaganfällen bei Vorhofflimmern in Deutschland

Pharmacology of Vitamin K Antagonists

Contact Info

Product

Resources

About